Difference between revisions of "Mianserine-citalopram"

From Psychiatrienet
Jump to: navigation, search
Line 3: Line 3:
 
| to = citalopram  
 
| to = citalopram  
 
| stop =  
 
| stop =  
* '''Day 0:''' gradually reduce dosage of mianserine to a maximum of 60 mg/ day.
+
* '''Before day 1:''' gradually reduce dosage of mianserine to a maximum of 60 mg/ day.
 
* '''Day 1:''' reduce a dosage of 60 mg/day to 30 mg/day.
 
* '''Day 1:''' reduce a dosage of 60 mg/day to 30 mg/day.
 
| start =   
 
| start =   

Revision as of 16:07, 17 November 2009

Mianserine
Type Antidepressant
Group other
links
PubChem 4184
PubMed Mianserine
Kompas (Dutch) Mianserine
Wikipedia Mianserine
Citalopram
Type Antidepressant
Group SSRI
links
ATC-code N06AB04
Medscape Citalopram
PubChem 2771
PubMed Citalopram
Kompas (Dutch) citalopram
Wikipedia citalopram

Switch medication from mianserine to citalopram.

Nietinrijdenbord.png Stop mianserine
  • Before day 1: gradually reduce dosage of mianserine to a maximum of 60 mg/ day.
  • Day 1: reduce a dosage of 60 mg/day to 30 mg/day.
Eenrichtingbord.png Start citalopram
  • Day 1: simultaneously start citalopram/escitalopram in a normal dosage of 20 mg/day, respectively 10 mg/day.
  • Day 8: stop administration of mianserine and only continue administration of citalopram/escitalopram.
  • If necessary, increase the dosage of citalopram/escitalopram.
Infobord.png More information
  • Caution with this switch is necessary, because citalopram/escitalopram slows the metabolism of mianserine via CYP2D6.
The editors of psychiatrienet.nl take the greatest care to provide up-to-date and accurate information on this site. Nevertheless, mistakes and omissions cannot be entirely excluded. No rights devolve from the information provided. The editors and other providers of information to this site accept no responsibility for the content of this site or for the information provided therein; neither do they accept responsibility for possible damages which may derive from the use of the information on this site or from the linked sites. The editorial board accepts no responsibility for the content of the (linked) sites, for access to them, or for the products and services on these sites, nor for the occurrence of errors, viruses, and/or disruptions in service.